Myqorzo is now available for rare heart condition at a $108,400 annual price

Cytokinetics has launched Myqorzo (aficamten), a new therapy to improve functional capacity and symptoms in adults with obstructive hypertrophic cardiomyopathy (oHCM). Myqorzo is available as 5 mg, 10 mg, 15 mg, and 20 mg tablets with a wholesale acquisition cost of $108,400 annually.

Hypertrophic cardiomyopathy is a disease characterized by the abnormal thickening of the cardiac muscle, which is the middle layer of the heart. This results in symptoms such as chest pain, dizziness, shortness of breath or fainting during physical activity. It is the most common monogenetic inherited cardiac disorder, with approximately 300,000 patients diagnosed and another 400,000 to 800,000 patients remaining undiagnosed in the United States.

Company officials said they are committed to supporting patients with the Myqorzo & You program, a personalized program for U.S. patients to help navigate the treatment journey, provide disease and product education, and offer support with insurance benefits investigations or financial assistance for those eligible.

For patients with commercial insurance, the company offers a free trial offer for one month’s supply, $5 copay card and a bridge program for those who face initial insurance denial, as well as $0 for eligible echocardiogram reimbursement for out-of-pocket costs not covered by insurance.

The terms of the copay program say insurance company accumulator or maximizer programs will limit the benefits, and indicates these programs are considered a violation of the terms. The program uses advanced logic to identify whether a claim for an enrolled patient is subject to an “accumulator” or “maximizer” program. With accumulator programs, the copay assistance does not count for the patient’s deductible or out-of-pocket (OOP) maximum. For copay maximizers, a patient can enroll with a third party that will set costs at the highest funds. Through this, patients would incur the minimum OOP cost, but the assistance funds would not count toward the deductible.

Cytokinetics said that its goal was to reach parity insurance coverage with the cardiac myosin inhibitor Camzyos (mavacamten) from Bristol Myers Squibb. As of the third quarter of 2025, insurance coverage for Camzyos was 34% commercial and 59% Medicare.

Myqorzo is designed to reduce heart muscle contraction by binding directly to cardiac myosin, a protein that regulates heart contractions. It was approved in December 2025 based on the results of the pivotal phase 3 clinical trial, SEQUOIA-HCM. The study randomly assigned 282 participants to receive Myqorzo or a placebo for 24 weeks.

Results showed that Myqorzo significantly improved exercise capacity compared with placebo. Additional analyses also showed that the investigational molecule was associated with cardiac remodeling and improvements in heart structure and function.

The results were published in the New England Journal of Medicine in May 2024.

Myqorzo is available through a Risk Evaluation and Mitigation Strategy (REMS) program, an FDA drug-safety program. Myqorzo carries a boxed warning about the risk of heart failure. The therapy reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction, a condition where the heart muscle becomes weak and can’t pump blood efficiently. Echocardiogram assessments are required prior to and during treatment to monitor for systolic dysfunction.